title: St John's wort or sertraline? Randomized controlled trial in primary care.
abstract: OBJECTIVE
  To compare the change in severity of depressive symptoms and occurrence of side effects in primary care patients treated with St John's wort (SJW) and sertraline.
  
  
  METHODS
  Double-blind, randomized 12-week trial.
  
  
  METHODS
  Community-based offices of 12 family physicians practising in greater Montreal, Que.
  
  
  METHODS
  Eighty-seven men and women with major depression and an initial score of > or = 16 on the Hamilton Rating Scale for Depression (Ham-D).
  
  
  METHODS
  Patients were randomized to treatment with either sertraline (50 to 100 mg/d) or SJW (900 to 1800 mg/d) in a double-blind fashion. Assessment of depression was done at entry and at 2, 4, 8, and 12 weeks using the Ham-D, the Beck Depression Inventory (BDI), and a questionnaire asking about compliance and side effects.
  
  
  METHODS
  Changes from baseline in Ham-D and BDI scores and self-reported side effects.
  
  
  RESULTS
  There were no important differences in changes in mean Ham-D and BDI scores (using intention-to-treat analysis), with and without adjustment for baseline demographic characteristics, between the two groups at 12 weeks. Significantly more side effects were reported in the sertraline group than in the SJW group at 2 and 4 weeks' follow up.
  
  
  CONCLUSIONS
  The more benign side effects of SJW make it a good first choice for this patient population.
authors.affiliation: Emergency Department, St Mary's Hospital Centre, 3830 Lacombe Ave, Montreal, QC. gerald.vangurp@mcgill.ca
authors.forename: Gerald
authors.initials: G
authors.lastname: van Gurp
authors.forename: Greg B
authors.initials: GB
authors.lastname: Meterissian
authors.forename: Laura N
authors.initials: LN
authors.lastname: Haiek
authors.forename: Jane
authors.initials: J
authors.lastname: McCusker
authors.forename: François
authors.initials: F
authors.lastname: Bellavance
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020902:Hypericum / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D020280:Sertraline / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D010936:Plant Extracts; D020280:Sertraline